G. Steve Arnold

Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee.

Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC.

Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

QuatroBio LLC engages in drug development services. The company was founded by Moise A. Khayrallah on September 4, 2014 and is headquartered in Morrisville, NC.

Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC.

Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials.